Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

atment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, Firdapse, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of GALNS, Firdapse, PEG-PAL, BMN-673, BMN-701 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono'
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
3. BioMarin to Present at the Baird Health Care Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. BioMarin Announces Second Quarter 2011 Financial Results
6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
8. BioMarin to Present at the William Blair Growth Stock Conference
9. BioMarin to Present at the Jefferies Global Healthcare Conference
10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
11. BioMarin Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
(Date:7/3/2015)... July 3, 2015 A global ... hypertension, diabetes and thyroid disorders in Latin ... a major conference dedicated to these diseases. ... Online , Manage Hypertension Online and ... by EXCEMED - combine the world,s top ...
(Date:7/2/2015)... BGI a annoncé aujourd,hui que son ... situé à Hong Kong ... Pathologists  (Collège des pathologistes américains, ou CAP). Les ... constituent le premier laboratoire clinique de ... du CAP en Chine, car il satisfait les ...
Breaking Medicine Technology:New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in ... Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, the new ... offering timely lawsuit updates and ovarian cancer warning information. The site is routinely updated ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location ... Star State. The premium frozen yogurt chain was listed as #22 on the Inc. 500 ... the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking Consultants specified ... of Minnesota, they knew it would save the university energy and maintenance costs. ... the total energy savings after installation was an impressive 89 percent, which resulted ...
(Date:7/2/2015)... ... ... “ LIFX ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... the market. , According to the U.S. Department of Energy, it’s very important to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... MONTREAL, Oct. 2 /PRNewswire-FirstCall/ - Haemacure Corporation,(TSX:HAE), a ... Mr. Joseph Galli, Chairman and Chief Executive,Officer, will ... will be,speaking on Wednesday, October 3, 2007 at ... City. About BioContact Quebec 2007 BioContact ...
... Promoted from Head of North America, PITTSBURGH, ... ),today announced the appointment of Heather Bresch as ... of North America and Chief,Integration Officer. As Chief ... global commercial and technical operations,strategic planning, business development ...
... Oct. 2 MEDRAD,s Heilman Center,electro-mechanical manufacturing ... been,selected as a 2007 IndustryWeek magazine "Best ... plants that are on the leading edge ... and create,stimulating and rewarding work environments. ...
... - For some cancer patients, side effects impacting cognition ... According to a new survey, the cognitive impairment experienced ... be long-lasting and severely affect their personal and professional ... memory loss, difficulty with word recall and the inability ...
... PA, October 2, 2007 The first significant genetic ... reported. PMDD is a very severe form of ... PMDD is heritable, affects 5-8% of women, and is ... irritability, marked depressed mood, anger, headaches, weight gain and ...
... World,s First Pocket Ultrasound ... ... ) is ushering in a new era of medicine,with today,s launch of ... diagnostic ultrasound system is a,little larger than a common PDA, weighs only ...
Cached Medicine News:Health News:Presentation at Bio Contact Quebec 2007 2Health News:Mylan Appoints Heather Bresch as Chief Operating Officer 2Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 2Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 3Health News:Cognitive deficits lead to 'loss of self' among cancer patients 2Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 3
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... ToRCH Plus Control is a ... monitor the performance of the ... and assays. A weak positive ... you to monitor the performance ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: